The drug and medical device maker Johnson & Johnson kicked off the healthcare earnings season with a better-than-anticipated report early Wednesday, as sales and earnings came in above expectations.That’s a good sign for the healthcare sector,

Plus, Adelita Grijalva wins the Democratic primary in the race for a House seat in Arizona. The seat was left vacant by her father Raúl Grijalva, who died in March.

Johnson & Johnson raised its full-year sales forecast on Wednesday after beating estimates for second-quarter profit on strong demand for its cancer drug, Darzalex, and strength in its medical device business.

During a conversation with @EdEastonJr, Texas Longhorns legend Derrick Johnson praised Kansas City Chiefs wide receiver Xavier Worthy's progress

OL Masterminds, the brainchild of Johnson and O-line guru Duke Manyweather, is an annual summit for linemen who want to share tricks of the trade and learn for themselves how to up their game.

C.J. Gardner-Johnson helped the Eagles win the Super Bowl in February, but he was traded to the Texans in March. And Gardner-Johnson thinks the Eagles got rid of him because they don’t like his competitive approach. Gardner Johnson was asked on The Pivot podcast why he thinks he’s not an Eagle anymore.

In two seasons with the Eagles, Gardner-Johnson recorded 126 tackles, 20 pass breakups, and 12 interceptions. He brought a much-needed edge to a defense that needed intensity, and that energy catapulted Philadelphia to another championship.

There's been a lot of talk about why C.J. Gardner-Johnson was traded from the Eagles to the Texans. The safety joined "The Pivot" to discuss that and the story behind his Super Bowl parade shirt.

Johnson & Johnson expects full-year earnings in the range of $10.80 to $10.90 per share, with revenue in the range of $93.2 billion to $93.6 billion. This story was generated by Automated Insights ( http://automatedinsights.com/ap) using data from Zacks Investment Research. Access a Zacks stock report on JNJ at https://www.zacks.com/ap/JNJ

Adjusted earnings per share for the quarter to June 29 fell to $2.77 from $2.82 in the same period a year ago, and topped the average analyst EPS estimate compiled by FactSet of $2.68.